Net Loss Per Share Attributable to Common Stockholders (Tables)

6 Months Ended

Jun. 30, 2022

Earnings Per Share [Abstract]

Weighted-Average Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share as They Had Anti-Dilutive Effect

The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share for the periods presented as they had an anti-dilutive effect:

	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Options to purchase common stock		1,598,495		1,055,116		1,375,969		940,932
Contingently issuable common stock prior to exchange of    Vaccinex Products, LP units		-		1,080,857		-		1,114,058
Contingently issuable common stock prior to exchange of    VX3 units		-		1,142,474		-		1,225,751